Objective:To explore the long-term efficacy of virtual reality exposure therapy (VRET) for acrophobia.Method:Sixty patients with acrophobia who visited the Nanjing Brain Hospital Affiliated to Nanjing Medical University from October 2018 to January 2021 were selected and randomly divided into VRET group ( n=30) and imaginary exposure therapy (IET) group ( n=30) using a block random number table method. The VRET group received VRET treatment, while the IET group received IET treatment. Both groups received treatment twice a week for 3 weeks. At baseline and after treatment, the acrophobia questionnaire (AQ) and attitude towards high questionnaire (ATHQ) were used to assess the patients' acrophobia symptoms, and the behavioral avoidance test (BAT) was used to assess the patients' level of avoidance when facing high altitude situations. During the 2-year follow-up after treatment, AQ and ATHQ were used to evaluate the patients' acrophobia symptoms. The repeated measures ANOVA and covariance analysis were used to analyze the data using SPSS 27.0 software. Result:(1) Repeated measures ANOVA showed that there was no significant interaction effect of AQ-anxiety, AQ-avoidance, and ATHQ scores between the two groups before and after treatment ( F=1.37, 1.95, 0.21, all P>0.05), while the time main effect of AQ-anxiety ( F=43.29) and ATHQ score ( F=13.35) was significant (both P<0.05), and the time main effect and group main effect of AQ-avoidance score were significant ( Ftime=62.84, Fgroup=5.65, both P<0.05). The AQ-avoidance scores of the VRET group(6.19±3.60, 8.25±3.80) were significantly lower than those of the IET group (9.60±3.74, 12.00±4.57)after treatment and during the follow-up period (both P<0.05).(2)After controlling for the baseline initial values of BAT in the two groups, the VRET group had a lower corrected BAT score (1.51 ± 0.72) than the IET group (4.39 ± 0.75) ( F=55.81, P<0.001), indicating that the efficacy of the VRET group was significantly better than that of the IET group. Conclusion:VRET significantly reduces acrophobia symptoms and behavioral avoidance level in patients with acrophobia, demonstrating superior efficacy compared to IET in both immediate and long-term effects.

Objective:To explore the long-term efficacy of virtual reality exposure therapy (VRET) for acrophobia.Method:Sixty patients with acrophobia who visited the Nanjing Brain Hospital Affiliated to Nanjing Medical University from October 2018 to January 2021 were selected and randomly divided into VRET group ( n=30) and imaginary exposure therapy (IET) group ( n=30) using a block random number table method. The VRET group received VRET treatment, while the IET group received IET treatment. Both groups received treatment twice a week for 3 weeks. At baseline and after treatment, the acrophobia questionnaire (AQ) and attitude towards high questionnaire (ATHQ) were used to assess the patients' acrophobia symptoms, and the behavioral avoidance test (BAT) was used to assess the patients' level of avoidance when facing high altitude situations. During the 2-year follow-up after treatment, AQ and ATHQ were used to evaluate the patients' acrophobia symptoms. The repeated measures ANOVA and covariance analysis were used to analyze the data using SPSS 27.0 software. Result:(1) Repeated measures ANOVA showed that there was no significant interaction effect of AQ-anxiety, AQ-avoidance, and ATHQ scores between the two groups before and after treatment ( F=1.37, 1.95, 0.21, all P>0.05), while the time main effect of AQ-anxiety ( F=43.29) and ATHQ score ( F=13.35) was significant (both P<0.05), and the time main effect and group main effect of AQ-avoidance score were significant ( Ftime=62.84, Fgroup=5.65, both P<0.05). The AQ-avoidance scores of the VRET group(6.19±3.60, 8.25±3.80) were significantly lower than those of the IET group (9.60±3.74, 12.00±4.57)after treatment and during the follow-up period (both P<0.05).(2)After controlling for the baseline initial values of BAT in the two groups, the VRET group had a lower corrected BAT score (1.51 ± 0.72) than the IET group (4.39 ± 0.75) ( F=55.81, P<0.001), indicating that the efficacy of the VRET group was significantly better than that of the IET group. Conclusion:VRET significantly reduces acrophobia symptoms and behavioral avoidance level in patients with acrophobia, demonstrating superior efficacy compared to IET in both immediate and long-term effects.

OBJECTIVE：To inves tigate the application effect and safety of modified compound polyethylene glycol electrolyte powder（SF-PEG）in intestinal preparation method for patients with constipation undergoing colonoscopy. METHODS ：From Jan. 2020 to Aug. 2020，160 patients with constipation undergoing colonoscopy in anorectal department of the affiliated hospital of North Sichuan Medical College were randomly divided into observation group and control group ，with 80 cases in each group. The patients in the control group took 2 boxes of SF-PEG （mixed into 3 000 mL warm water ）orally at 3：00 a.m. on the day of examination，and finished within 2 hours. The patients in the observation group took 1 box of SF-PEG （mixed into 1 500 mL warm water）at 20：00 the night before the examination and 5：00 in the morning of the day of examination ，and drank it within 1 hour；1 bottle of Dimethylsiloxane powder （mixed into 75 mL warm water ）was taken orally at 7：00 a.m. on the inspection day. The satisfaction of intestinal preparation ，intestinal bubble score ，operation time of colonoscopy ，detection of polyps ，tolerance rate ， acceptance rate of repeating intestinal preparation of patients and incidence of adverse reactions were compared between the two groups. RESULTS ：The patients of 2 groups successfully completed bowel preparation and colonoscopy. The intestinal preparation total satisfaction rate ，intestinal bubble satisfaction rate ，polyp detection rate ，tolerance rate and repeating intestinal preparation acceptance rate of patients of observation group were significantly higher than control group （P＜0.05），while the incidence of nausea and vomiting and total incidence of adverse reactions were significantly lower than control group （P＜0.05），and the operation time of colonoscopy was significantly shorter than control group （P＜0.05）. CONCLUSIONS ：Oral administration of SF-PEG in batches combined with Dimethylsiloxane powder for bowel preparation in patients with constipation before colonoscopy have the advantages of high satisfaction with bowel preparation ，less intestinal bubbles ，short operation time ，high detection rate of polyps，high tolerance rate of patients ，high acceptance rate of repeating intestinal preparation and less adverse reactions. It is a safe and effect method for intestinal preparation.

Objective Using olfactory task functional magnetic resonance imaging (fMRI) to investigate the difference in brain olfactory activation between patients with subjective cognitive decline and normal elderly subjects, and to explore the objective image markers for early identification and evaluation the progression from SCD to Alzheimer′s disease (AD). Methods Twenty patients with SCD (SCD group) and twenty matched normal elderly subjects (NC group) were recruited from the community from March 2017 to December 2018. A full neuropsychological scale tests battery, olfactory behavioral tests and olfactory task?fMRI were performed. The differences between olfactory behavior, neuropsychological scales, and task?fMRI brain activation between the two groups were tested. Further, brain regions, which had significantly different activations under task?fMRI, were used as seeds for resting state functional connectivity (FC) analysis. Finally, the correlations between brain activation and olfactory behavior along with clinical neuropsychological scale tests were examined. Results The results of this study showed SCD had a significant decrease in olfactory behavior (olfactory recognition ability) compared with NC (t=-3.042, P<0.01), and there was no statistically significant difference in olfactory threshold. Significant declines were also observed in the SCD self?rating scale (t=6.973, P<0.01), the immediate (t=-4.623, P<0.01) and delayed (t=-2.746, P<0.01) testing of Philadelphia word learning, while the remaining neuropsychological scales were normal. In the olfactory task?fMRI, activation of bilateral primary olfactory cortical regions was significantly reduced in SCD patients, including bilateral entorhinal cortex, amygdala, piriform cortex, anterior olfactory nucleus, and head of the hippocampus. The resting state functional connectivity with the primary olfactory cortex (POC) as the seed showed that the functional connectivity between the olfactory system and the default model network (DMN) of SCD patients was significantly weakened (AlphaSim correction with voxel level P<0.01 and cluster level P<0.05). The Beta value of the left POC was significantly positively correlated with the olfactory threshold and Montreal cognitive assessment (MoCA) (r=0.329, P=0.041; r=0.317, P=0.046). Partial correlation analysis indicated that there was a significantly positive correlation between the FC of the left POC with the right/left inferior frontal gyrus, the left frontal middle gyrus and the right inferior parietal, and the score of immediate Philadelphia word learning test(r=0.411, P=0.008; r=0.400, P=0.011; r=0.329, P=0.003; r=0.454, P=0.003). The FC between the left POC and the right inferior temporal gyrus was negatively correlated with the score of trail making test (TMT) B, and the FC between the left POC and the right inferior was negatively correlated with score of language fluency test (r=-0.317, P=0.047; r=-0.333, P=0.036). The FC between the right POC and the left inferior parietal was positively correlated with the score of immediate Philadelphia word learning (r=0.315, P=0.048), while the FC between right POC and left middle occipital gyrus was negatively corrected with Language Fluency Test (r=-0.403, P=0.01). Conclusion Olfactory function has been impaired in SCD patients with normal standard cognition and phychiatric rating scales, and the changes in the activation of the primary olfactory cortex, such as the entorhinal cortex, may be an early neural circuit damage biomarker for objective evaluation of SCD.